Australia is gain access to potentially transformative treatment for obesity: Retatrutide. The dual agonist – working on both GLP-1 and GIP receptors – has promising outcomes in international trials, suggesting substantial decreases in BMI. While availability hasn't occurred with TGA, several Australians dealing with being read more overweight